In vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis

The aim of this study was to investigate the in vitro antifungal potency of the moronecidin-like peptide against Candida albicans, Candida glabrata, and Candida tropicalis.

To evaluate the antifungal effect of moronecidin-like peptide, the protocol presented in CLSI M27-A3 and CLSI M27-S4 was used and the minimum inhibitory concentration was determined.

The minimum inhibitory effect of moronecidin-like peptide composition was 8 μg/ml for Candida tropicalis and Candida albicans and 32 μg/ml for Candida glabrata. The MIC of nystatin was determined to be 1.25 μg/ml for Candida glabrata and Candida albicans and 0.625 μg/ml for Candida tropicalis strains. The MFC composition of the moroneci- din-like peptide was determined for Candida tropicalis and Candida albicans strains 8 μg/ml and for Candida glabrata strain 64 μg/ml. The results of cytotoxicity and hemolysis of the moronecidin peptide test on macrophage showed that moronecidin peptide has no cytotoxicity and toxicity properties.

According to the results of the present study, the moronecidin-like peptide could be a new strategy in the treat- ment of infections caused by Candida strains. The discovery of the exact mechanism of which requires extensive clinical studies in this field.